Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus

Journal of Rheumatology

Volumn 32, Issue 4, 2005, Pages 622-628

  Mo, Yin Mok ^a,b   Chan, Eric Yuk Tat ^a   Fong, Daniel Yee Tak ^a   Leung, Kate Fung Shan ^a   Woon, Sing Wong ^a   Chak, Sing Lau ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti 2 glycoprotein I antibodies; Anticardiolipin antibodies; Antiphospholipid syndrome; Pregnancy outcome; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; WARFARIN;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CARDIOVASCULAR RISK; CHINA; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; OUTCOMES RESEARCH; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ABORTION, HABITUAL; ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HONG KONG; HOSPITALS, UNIVERSITY; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS;

EID: 17144382450     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Gourley IS, McMillan SA, Bell AL. Clinical features associated with a positive anticardiolipin antibody in Irish patients with systemic lupus erythematosus. Clin Rheumatol 1996;15:457-60.
2. Diri E, Cucurull E, Gharavi AE, et al. Antiphospholipid (Hughes) syndrome in African-Americans: IgA aCL and anti-beta-2 glycoprotein-I is the most frequent isotype. Lupus 1999;8:263-8.
3. Cucurull E, Espinoza LR, Mendez E, et al. Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards. Lupus 1999;8:134-41.
4. Jones HW, Ireland R, Senaldi G, et al. Anticardiolipin antibodies in patients from Malaysia with systemic lupus erythematosus. Ann Rheum Dis 1991;50:173-5.
5. Shrivastava A, Dwivedi S, Aggarwal A, Misra R. Anti-cardiolipin and anti-beta-2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures. Lupus 2001;10:45-50.
6. Aguirre V, Cuchacovich R, Barria L, et al. Prevalence and isotype distribution of antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus. Lupus 2001;10:75-80.
7. Liu HS, Kho BC, Chan JC, et al. Venous thromboembolism in the Chinese population - experience in a regional hospital in Hong Kong. Hong Kong Med J 2002;8:400-5.
8. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Group d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657-60.
9. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998;128:737-40.
10. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999;7:1309-11.
12. Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibodies: isotype distribution and phospholipids specificity. Ann Rheum Dis 1987;46:1-6.
13. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. 'Anticardiolipin' autoantibodies recognize β2-glycoprotein I in the absence of phospholipids. Importance of Ag density and bivalent binding. J Immunol 1995;75:1361-7.
14. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986;68:869-74.
15. Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983;79:678-82.
16. Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990;112:682-98.
17. Cervera R, Khamashta MA, Font J, et al. European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine Baltimore 2003;82:299-308.
18. Finazzi G. Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996;100:530-6.
19. Alarcon-Segovia D, Perez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992;21:275-86.
20. Cucurull E, Gharavi AE, Diri E, Mendez E, Kapoor D, Espinoza LR. IgA anticardiolipin and anti-beta-2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999;318:55-60.
21. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-8.
22. Shah NM, Khamashta MA, Atsumi T, Hughes GRV. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998;7:3-6.
23. Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997;96:4380-4.
24. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002;87:518-22.
25. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology Oxford 2002;41:924-9.
26. Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 2003;12:518-23.
27. Kittner SJ, Gorelick PB. Antiphospholipid antibodies and stroke: an epidemiological perspective. Stroke 1992;23 Suppl:I19-22.
28. Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989;68:353-65.
29. Finazzi G. The Italian Registry of antiphospholipid antibodies. Haematologica 1997;82:101-5.
30. Font J, Lopez-Stoto A, Cervera R, et al. Antibodies to thromboplastin in systemic lupus erythematosus: isotype distribution and clinical significance in a series of 92 patients. Thromb Res 1997;86:37-48.
31. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine 1989;68:366-74.
32. Lockshin MD, Druzin ML, Goei S, et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985;313:151-6.
33. Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985;21:1322-6.
34. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anti-cardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995;86:555-9.
35. Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynecol 1993;100:909-13.
36. Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castilo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology Oxford 2002;41:643-50.
37. Harris EN, Chan JKH, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 1986;146:2153-6.
38. Escalante A, Brey RL, Mitchell BD, Dreiner U. Accuracy of anti-cardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995;98:559-65.
39. Day HM, Thiagarajan P, Ahn C, Reveille JD, Tinker KF, Arnett FC. Autoantibodies to β2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid syndrome: clinical correlations in comparison with other antiphospholipid antibody test. J Rheumatol 1998;25:667-74.
40. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR. Specificity of ELISA for antibody to β2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996;35:1239-43.
41. Balestrieri F, Tincani A, Spatola L, et al. Anti-beta-2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? Lupus 1995;4:122-30.
42. Faden D, Tincani A, Tanzi P, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta 2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur J Obstet Gynaecol Reprodu Biol 1997;73:37-42.